

Breast implants and A.L.C.L.

A.De Mey
Plastic Surgery
Free University Brussels

A.L.C.L.

- Non Hodgkin Lymphoma
- Anormal growth of T cells
- CD30 Surface marker
- Anaplastic lymphoma kinase(ALK) : -

A.L.C.L.

- Extremely rare
- Genetic background
- Chronic inflammatory reaction
- Immunodeficiencies
- Auto immune disease

A.L.C.L.

- Systemic ALCL : aggressive
- Cutaneous : favorable

A.L.C.L.

In breast implants

- Presence in the fibrous capsule
- Presence in the seroma around
- Same type as cutaneous ALCL
- CD30 and ALK-

A.L.C.L.

In breast implants

- First breast implant 1962
- 10 millions breast implants worldwide
- First report A.L.C.L. 2002
- First FDA report 2010 on a 2007 case
- First FDA recommandation 2011

Plastic Surgery Global Open 2015

- Should be called BIA-ALCL
- Late seroma > 1y should be examined
- Surgical removal of the implant and the capsule
- Surveillance follow-up 5 y
- Good prognosis
- Chemo and radiotherapy not recommended

Belgian Agency Recommendations

- ALCL extremely rare
- Higher incidence in the breast periprosthetic capsula
- Necessary report of all cases to the Agency
- Multidisciplinary protocol

Federale agentschap voor
geneesmiddelen en gezondheids-
producten

Agence fédérale des médicaments
et produits de santé

RBSPS proposal

- International Collaboration of Breast Implant Registry Activities (ICOBRA)
- Standardised data base set for registration of breast implants developed by the Australasian society of plastic surgery